Molecular indicators of breast cancer prognosis and prediction of treatment response
US7622251B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Nov 4, 2005 |
| Grant date | Nov 24, 2009 |
| Priority date | — |
| Expiry date | Nov 4, 2025 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG16B25/00
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to quantitative molecular indicators that can guide clinical decisions in breast cancer, such as estrogen receptor (ESR1)-positive, lymph node-negative breast cancer. In particular, the invention concerns certain genes, the varied expression of which indicates the likelihood of recurrence of surgically resected breast cancer in patients who are not treated with a therapeutic agent in the adjuvant setting. In addition, the invention concerns the use of quantitative measurement of the expression of certain genes, including the ESR1 gene, that measure as a continuous variable, to determine (a) the likelihood of a beneficial response to the anti-estrogen therapeutic agent, such as tamoxifen; and (b) the potential magnitude of beneficial response to chemotherapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.